SMNRW
Semnur Pharmaceuticals, Inc.
Key Financials
Revenue
$50.0M
0.0%
Operating Income
$-160416000
↓ 9627.5%
Total Liabilities
$22.1M
↑ 111.8%
EPS (Diluted)
$-0.78
↓ 3800.0%
Total Assets
$1.3M
↓ 85.1%
Shareholders' Equity
$-20750000.00
↓ 99.2%
Cash & Equivalents
$20000.00
↑ 66.7%
Net Income
$-160416000
↓ 95781.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 10-Q | 8/10/2026 | View on SEC |
| 424B3 | 7/7/2026 | View on SEC |
| 8-K | 7/7/2026 | View on SEC |
| 424B3 | 7/1/2026 | View on SEC |
| SCHEDULE 13D/A | 6/26/2026 | View on SEC |
| 4 | 6/26/2026 | View on SEC |
| 8-K | 6/25/2026 | View on SEC |
| 424B3 | 6/15/2026 | View on SEC |
| 424B3 | 6/15/2026 | View on SEC |
| EFFECT | 5/18/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | SMNRW |
| Company Name | Semnur Pharmaceuticals, Inc. |
| CIK | 1913577 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | OTC |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (650) 516-4310 |